Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118833 · ClinicalTrials.gov registry record · Phase 2
St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)
A Phase 2 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00118833 is a Phase 2 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 56 participants.
The verdict
NCT00118833, a Phase 2 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study will determine whether the herbal product St. John's wort is safe and effective in treating generalized social anxiety disorder (GSAD). Study hypothesis: Hypericum perforatum (St. John's wort) is more effective in treating GSAD than placebo.
Interventions
- DRUG Hypericum perforatum (St. John's wort)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2002-08 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118833
The ClinicalTrials.gov registry entry for NCT00118833 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hypericum perforatum (St. John's wort) is the first listed.
NCT00118833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118833 about?
NCT00118833 is a clinical study titled "St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)". This study will determine whether the herbal product St. John's wort is safe and effective in treating generalized social anxiety disorder (GSAD). Study hypothesis: Hypericum perforatum (St. John's wort) is more effective in treating GSAD than placebo.
What is the current status of trial NCT00118833?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2002-08. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00118833?
The interventions under investigation include: Hypericum perforatum (St. John's wort) (DRUG).
Who is sponsoring clinical trial NCT00118833?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.